LATEST NEWS
GenVivo Latest News
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 8, 2024
Read More >
GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib Clinical Trial Evaluating GEN2, a Personalizing, Gene Vector Immunotherapy, in Patients with Advanced Solid Tumors
Jun 27, 2024
Read More >
GenVivo to Present Pipeline Programs at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 8, 2024
Read More >
GenVivo to Present at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apr 10, 2024
Read More >
GenVivo to Present at the 2024 BioProcess International (BPI) US West Annual Meeting
Mar 12, 2024
Read More >
GenVivo to Present at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 4, 2023
Read More >
